Cargando…

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer

The aims of this work were to characterize ipatasertib exposure–response (E‐R) relationships in a phase II study and to quantitatively assess benefit‐risk using a clinical utility index approach to support ipatasertib phase III dose selection in patients with metastatic castration‐resistant prostate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Rui, Poland, Bill, Wada, Russ, Liu, Qi, Musib, Luna, Maslyar, Daniel, Cho, Eunpi, Yu, Wei, Ma, Han, Jin, Jin Yan, Budha, Nageshwar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482275/ https://www.ncbi.nlm.nih.gov/pubmed/30762302 http://dx.doi.org/10.1002/psp4.12394

Ejemplares similares

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
por: Jing, Jing, et al.
Publicado: (2022)

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study
por: Kotani, Naoki, et al.
Publicado: (2022)

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
por: O'donnell, Jillian, et al.
Publicado: (2023)

Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
por: Laterza, Maria Maddalena, et al.
Publicado: (2021)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Impact of Physiologically Based Pharmacokinetic Models on Regulatory Reviews and Product Labels: Frequent Utilization in the Field of Oncology
por: Yoshida, K, et al.
Publicado: (2017)

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
por: Shi, Zhen, et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
por: Jiang, Xuemin, et al.
Publicado: (2021)

Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
por: Sun, Li, et al.
Publicado: (2018)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches
por: Läubli, Heinz, et al.
Publicado: (2022)

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics
por: Lu, Tong, et al.
Publicado: (2017)

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
por: Raju, Govinda Nanjaiah Laxmana, et al.
Publicado: (2022)

Utilization of FMOC-3F-PHE hydrogel for encapsulation of Zanthoxylum armatum and Cinnamomum camphora oil for enhancing their antibacterial activity
por: Shakya, Nasla, et al.
Publicado: (2022)

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
por: Netterberg, Ida, et al.
Publicado: (2018)

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
por: Lu, Dan, et al.
Publicado: (2016)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires
por: Svensson, Robin J, et al.
Publicado: (2021)

Time to Rethink the Current Paradigm for Assessing Kidney Function in Drug Development and Beyond
por: Sharma, Ashish, et al.
Publicado: (2021)

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
por: Desai, Jayesh, et al.
Publicado: (2023)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
por: Turner, Nicholas, et al.
Publicado: (2021)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Differential responses to (223)Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe
por: Guerra Liberal, Francisco D. C., et al.
Publicado: (2022)

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy
por: Echevarria, Michelle I., et al.
Publicado: (2016)

Ampicillin Dosing in Premature Infants for Early-onset Sepsis: Exposure-driven Efficacy, Safety, and Stewardship
por: Le, Jennifer, et al.
Publicado: (2022)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

The standardized exposure index for digital radiography: an opportunity for optimization of radiation dose to the pediatric population
por: Seibert, J. Anthony, et al.
Publicado: (2011)

Being Design Driven: Why You Care
por: Hall, Russ
Publicado: (2010)

Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection
por: Barisiene, Marija, et al.
Publicado: (2020)

Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection
por: Chiu, Shih-Ting, et al.
Publicado: (2021)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

The Opsonic Index and Its Utility
Publicado: (1907)

Enhancing Prolonged Exposure therapy for PTSD using physiological biomarker-driven technology
por: Back, Sudie E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v1hkioaiom3grpre3lb9jsfpu4